SOUTH SAN FRANCISCO--Exelixis announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute to elucidate how NCI anti-cancer compounds work. In the three-year collaboration, Exelixis will use its proprietary model system genetics technology to identify the mechanism of action for NCI compounds that have a demonstrated in vivo or in vitro anti-cancer activity.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.